<DOC>
	<DOC>NCT01096979</DOC>
	<brief_summary>This is a double-masked evaluation of the safety and efficacy of LIPO-102 for the reduction of subcutaneous abdominal adiposity.</brief_summary>
	<brief_title>An Evaluation of the Safety and Efficacy of LIPO-102 for the Reduction of Subcutaneous Abdominal Adiposity</brief_title>
	<detailed_description />
	<mesh_term>Obesity</mesh_term>
	<criteria>Male or non pregnant female Good general health Sufficient abdominal fat for injections Signed informed consent BMI greater than or equal to 18 and less than 28 kg/m2 History of stable weight in past 3 months Known hypersensitivity to study drugs Treatment with an investigational agent within 30 days of first dose</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Subcutaneous Adipose Tissue Reduction</keyword>
</DOC>